Abstract
Nonalcoholic fatty liver disease (NAFLD) is the most common type of liver disease. NAFLD is considered a multifactorial disease and a clinically relevant hepatic manifestation of metabolic syndrome. NAFLD is often accompanied by a constellation of metabolic and non-metabolic alterations, like dyslipidemia, insulin resistance in the liver and peripheral tissues, inflammation and oxidative stress; therefore, treatment of NAFLD should be directed at correcting all of these disturbances. The natural polyphenol curcumin has been the subject of increasing research for the treatment of NAFLD due to its lipid-modifying, antioxidant, anti-inflammatory, insulinsensitizing, anti-steatotic, and anti-fibrotic properties. The therapeutic efficacy of curcumin has been demonstrated in several experimental models of NAFLD, however, clinical evidence is still scarce. The present review summarizes the current knowledge on the impact of curcumin supplementation on different biochemical and histopathological features of NAFLD.
Keywords: Curcumin, steatosis, non-alcoholic steatohepatitis, dyslipidemia, inflammation.
Current Pharmaceutical Design
Title:Is There a Role for Curcumin Supplementation in the Treatment of Non-Alcoholic Fatty Liver Disease? The Data Suggest Yes
Volume: 23 Issue: 7
Author(s): Narges Amel Zabihi, Matteo Pirro, Thomas P. Johnston and Amirhossein Sahebkar
Affiliation:
Keywords: Curcumin, steatosis, non-alcoholic steatohepatitis, dyslipidemia, inflammation.
Abstract: Nonalcoholic fatty liver disease (NAFLD) is the most common type of liver disease. NAFLD is considered a multifactorial disease and a clinically relevant hepatic manifestation of metabolic syndrome. NAFLD is often accompanied by a constellation of metabolic and non-metabolic alterations, like dyslipidemia, insulin resistance in the liver and peripheral tissues, inflammation and oxidative stress; therefore, treatment of NAFLD should be directed at correcting all of these disturbances. The natural polyphenol curcumin has been the subject of increasing research for the treatment of NAFLD due to its lipid-modifying, antioxidant, anti-inflammatory, insulinsensitizing, anti-steatotic, and anti-fibrotic properties. The therapeutic efficacy of curcumin has been demonstrated in several experimental models of NAFLD, however, clinical evidence is still scarce. The present review summarizes the current knowledge on the impact of curcumin supplementation on different biochemical and histopathological features of NAFLD.
Export Options
About this article
Cite this article as:
Zabihi Amel Narges, Pirro Matteo, Johnston P. Thomas and Sahebkar Amirhossein, Is There a Role for Curcumin Supplementation in the Treatment of Non-Alcoholic Fatty Liver Disease? The Data Suggest Yes, Current Pharmaceutical Design 2017; 23 (7) . https://dx.doi.org/10.2174/1381612822666161010115235
DOI https://dx.doi.org/10.2174/1381612822666161010115235 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Molecular Insight and Binding Pattern Analysis of Shikonin as a Potential VEGFR-2 Inhibitor
Current Enzyme Inhibition Sodium Intake, Circulating Microvesicles and Cardiovascular Outcomes in Type 2 Diabetes
Current Diabetes Reviews Author Index To Volume 3
Current Topics in Medicinal Chemistry Editorial [Hot Topic: New Developments in the Prevention and Treatment of Vascular Disease - 2 Executive (Guest Editors: Manfredi Rizzo and Dimitri P. Mikhailidis)]
Current Pharmaceutical Design Severe Coagulation Disorder and Thrombocytopenia Associated with Tigecycline – Case Report and Review of Literature
Current Drug Safety Which Dose of Folic Acid Should Pregnant Diabetic Women Receive?
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Current Pharmacological Approach to Restore Endothelial Dysfunction
Cardiovascular & Hematological Agents in Medicinal Chemistry Reduction in Estimated Glomerular Filtration Rate (eGFR) Results in an Increased Risk of Spontaneous Hemorrhagic Transformation in Patients with Large-artery Atherosclerosis Stroke
Current Neurovascular Research Neuroplasticity Regulation by Noradrenaline in Mammalian Brain
Current Neuropharmacology Nutritional Interventions and Considerations for the Development of Low Calorie or Sugar Free Foods
Current Diabetes Reviews A Novel Monocyte-based Pyrogen Test Based on the Mechanism of Human Fever Reaction
Current Pharmaceutical Analysis AMPK as a New Attractive Therapeutic Target for Disease Prevention: The Role of Dietary Compounds AMPK and Disease Prevention
Current Drug Targets Non-Demented Individuals with Alzheimer’s Disease Neuropathology: Resistance to Cognitive Decline May Reveal New Treatment Strategies
Current Pharmaceutical Design Update on Statins: Hope for Osteoporotic Fracture Healing Treatment
Current Drug Targets Biopharmaceutical Powders Particle Formation and Formulation Considerations
Current Pharmaceutical Biotechnology VIP in Inflammatory Bowel Disease: State of the Art
Endocrine, Metabolic & Immune Disorders - Drug Targets Common Variant in VEGFA and Response to Anti-VEGF Therapy for Neovascular Age-Related Macular Degeneration
Current Molecular Medicine Patients with Increased Non-Ceruloplasmin Copper Appear a Distinct Sub-Group of Alzheimer's Disease: A Neuroimaging Study
Current Alzheimer Research Peroxisome Proliferator-Activated Receptor (PPAR) Gamma Agonists as Therapeutic Agents for Cardiovascular Disorders: Focus on Atherosclerosis
Current Pharmaceutical Design Which Treatment for Nonalcoholic Fatty Liver Disease?
Mini-Reviews in Medicinal Chemistry